Maternal T-cell engraftment impedes with diagnosis of a SCID-ADA patient

Clin Immunol. 2018 Aug:193:118-120. doi: 10.1016/j.clim.2018.01.004. Epub 2018 May 7.

Abstract

We describe the case of a child affected by severe combined immunodeficiency (SCID) with adenosine deaminase (ADA) deficiency showing a maternal T-cell engraftment, a finding that has never been reported before. The presence of engrafted maternal T cells was misleading. Although ADA enzymatic levels were suggestive of ADA-SCID, the child did not present the classical signs of ADA deficiency; therefore, the initial diagnosis was of a conventional SCID. However, ADA toxic metabolites and molecular characterization confirmed this diagnosis. Polyethylene glycol-modified bovine (PEG) ADA therapy progressively decreased the number of maternal engrafted T cells. The child was grafted with full bone marrow from a matched unrelated donor, after a reduced conditioning regimen, and the result was the complete immunological reconstitution.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase / deficiency*
  • Adenosine Deaminase / genetics
  • Adenosine Deaminase / metabolism*
  • Agammaglobulinemia / diagnosis*
  • Agammaglobulinemia / genetics
  • Agammaglobulinemia / therapy
  • Bone Marrow Transplantation*
  • Chimerism*
  • Diagnosis, Differential
  • Diagnostic Errors / prevention & control
  • Female
  • Humans
  • Infant
  • Maternal-Fetal Exchange / immunology*
  • Mothers
  • Pregnancy
  • Severe Combined Immunodeficiency / diagnosis*
  • Severe Combined Immunodeficiency / genetics
  • Severe Combined Immunodeficiency / therapy
  • T-Lymphocytes / physiology*
  • Treatment Outcome

Substances

  • Adenosine Deaminase

Supplementary concepts

  • Severe combined immunodeficiency due to adenosine deaminase deficiency